Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides

Core Viewpoint - NanoViricides, Inc. has filed for Orphan Drug Designation for NV-387 as a treatment for Measles with the US FDA, which could provide significant incentives if approved [1] Group 1: Company Developments - The company is a clinical stage leader in developing broad-spectrum antivirals using host-mimetic nanomedicine technology [1] - The application for Orphan Drug Designation (ODD) is aimed at enhancing the treatment options for Measles [1] Group 2: Regulatory Incentives - If granted, the orphan drug designation will provide the company with tax credits for qualified clinical trials [1] - The designation will exempt the company from certain user fees [1] - The company could gain potential market exclusivity for seven years post-approval [1]